GlassScriptPhysician profile
Michael Jerome Bratsch
NPI 1811927841
$17,453.32
in general payments reported to CMS, 2019-2025
57 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,798 · 2020: $1,369 · 2021: $1,108 · 2022: $4,245 · 2023: $2,529 · 2024: $2,857 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,801.22 | 2022 | |
| Lilly USA, LLC | $1,584.84 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,436.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,276.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,221.11 | 2019-2025 | |
| Novo Nordisk INC | $1,205.99 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $981.91 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Janssen Pharmaceuticals, INC | $835.03 | 2019-2024 | Spravato, Xarelto |
| Amgen INC. | $767.30 | 2019-2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $710.49 | 2021-2025 | |
| Abbvie INC. | $630.47 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $491.52 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $461.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $373.27 | 2019-2024 | |
| Viiv Healthcare Company | $303.72 | 2022-2025 | Apretude |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $301.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $225.09 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.62 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $161.12 | 2022-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $157.78 | 2019-2025 | Contrave, Nexlizet, Nexletol |
| Biohaven Pharmaceuticals, INC. | $152.73 | 2021 | |
| Shield Therapeutics INC | $144.16 | 2024 | |
| Paratek Pharmaceuticals, INC. | $124.41 | 2024-2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $120.91 | 2019-2025 | |
| Eisai INC. | $118.91 | 2019-2024 | |
| Antares Pharma, INC. | $113.26 | 2019-2024 | Xyosted |
| Gilead Sciences, INC. | $103.54 | 2019-2025 | |
| Exact Sciences Corporation | $101.36 | 2023-2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $92.97 | 2023 | Secuado |
| Shire North American Group INC | $87.63 | 2019 | |
| Dynavax Technologies Corporation | $85.77 | 2022-2025 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $83.47 | 2022-2023 | Qelbree |
| Corcept Therapeutics | $77.57 | 2024-2025 | Korlym |
| Medtronic, INC. | $77.00 | 2024-2025 | Intellis Adaptivestim, O-Arm |
| Sunovion Pharmaceuticals INC. | $70.92 | 2021-2022 | |
| Stryker Corporation | $70.58 | 2024 | Augment Injectable |
| Biogen, INC. | $69.32 | 2024 | Skyclarys |
| Dexcom, INC. | $67.74 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $55.82 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $52.76 | 2019-2023 | Seglentis, Livalo |
| Lundbeck LLC | $50.97 | 2023-2025 | Rexulti, Vyepti |
| Vertex Pharmaceuticals Incorporated | $49.21 | 2025 | |
| Sumitomo Pharma America, INC. | $37.36 | 2024-2025 | Gemtesa |
| Abiomed | $34.57 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $31.39 | 2019 | |
| Axsome Therapeutics, INC. | $28.24 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $26.11 | 2019 | |
| Corium, LLC | $24.49 | 2023 | Azstarys |
| Allergan, INC. | $24.40 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $21.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.60 | 2022 | |
| Tolmar, INC. | $19.13 | 2025 | Jatenzo |
| Aytu Biopharma, INC. | $18.85 | 2019 | |
| Horizon Therapeutics Plc | $18.30 | 2019 | |
| Medtronic USA, INC. | $17.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.30 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bratsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.